Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCABNASDAQ:CNTXNASDAQ:QNCXNASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.44+1.0%$0.34$0.24▼$3.53$25.98M1.08980,179 shs416,782 shsCNTXContext Therapeutics$0.94+0.0%$0.78$0.55▼$2.75$84.33M2.18409,382 shs40,456 shsQNCXQuince Therapeutics$1.13-7.9%$1.27$0.51▼$2.45$49.99M0.74248,775 shs544,928 shsUNCYUnicycive Therapeutics$0.65+1.3%$0.58$0.20▼$1.29$77.64M2.151.46 million shs232,775 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla0.00%+36.07%+18.03%-10.25%-82.65%CNTXContext Therapeutics0.00%+11.49%+43.49%+3.27%-33.34%QNCXQuince Therapeutics0.00%+24.18%-8.89%-28.49%+16.04%UNCYUnicycive Therapeutics0.00%+6.61%+4.23%+12.28%-37.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.9406 of 5 stars3.33.00.00.02.72.51.3CNTXContext Therapeutics1.9394 of 5 stars3.62.00.00.02.70.00.6QNCXQuince Therapeutics2.8199 of 5 stars3.63.00.00.02.70.81.3UNCYUnicycive Therapeutics3.4056 of 5 stars3.65.00.00.02.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$6.001,248.62% UpsideCNTXContext Therapeutics 3.13Buy$6.17555.96% UpsideQNCXQuince Therapeutics 3.29Buy$8.00606.09% UpsideUNCYUnicycive Therapeutics 3.25Buy$5.50747.98% UpsideCurrent Analyst Ratings BreakdownLatest BCAB, UNCY, CNTX, and QNCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/21/2025UNCYUnicycive TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/11/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/9/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/1/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.503/31/2025BCABBioAtlaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $4.003/24/2025QNCXQuince TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.003/21/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/21/2025CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.002/5/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M2.36N/AN/A$1.47 per share0.30CNTXContext TherapeuticsN/AN/AN/AN/A$0.74 per shareN/AQNCXQuince TherapeuticsN/AN/AN/AN/A$1.98 per shareN/AUNCYUnicycive Therapeutics$680K114.18N/AN/A($0.11) per share-5.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$123.46M-$1.44N/AN/AN/AN/A-187.30%-96.33%5/13/2025 (Estimated)CNTXContext Therapeutics-$23.96M-$0.49N/AN/AN/AN/A-58.76%-55.80%5/14/2025 (Estimated)QNCXQuince Therapeutics-$31.39M-$1.31N/AN/AN/AN/A-53.27%-22.73%5/12/2025 (Estimated)UNCYUnicycive Therapeutics-$30.54M-$1.07N/AN/AN/AN/AN/A-29.88%5/12/2025 (Estimated)Latest BCAB, UNCY, CNTX, and QNCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025N/ACNTXContext Therapeutics-$0.05N/AN/AN/AN/AN/A5/13/2025Q1 2025BCABBioAtla-$0.28N/AN/AN/AN/AN/A5/12/2025Q1 2025QNCXQuince Therapeutics-$0.24N/AN/AN/AN/AN/A5/12/2025N/AUNCYUnicycive Therapeutics-$0.14N/AN/AN/AN/AN/A3/27/2025Q4 2024BCABBioAtla-$0.40-$0.32+$0.08-$0.34N/AN/A3/27/2025Q4 2024UNCYUnicycive Therapeutics-$0.13-$0.26-$0.13-$0.26N/AN/A3/24/2025Q4 2024QNCXQuince Therapeutics-$0.19-$0.28-$0.09-$0.28N/A$0.17 million3/20/2025Q4 2024CNTXContext Therapeutics-$0.05-$0.04+$0.01N/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A3.113.11CNTXContext TherapeuticsN/A36.9136.91QNCXQuince Therapeutics0.339.539.53UNCYUnicycive TherapeuticsN/A3.613.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CNTXContext Therapeutics14.03%QNCXQuince Therapeutics30.75%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%CNTXContext Therapeutics3.04%QNCXQuince Therapeutics16.80%UNCYUnicycive Therapeutics24.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.40 million42.79 millionOptionableCNTXContext Therapeutics789.70 million72.72 millionNot OptionableQNCXQuince Therapeutics6044.12 million36.61 millionOptionableUNCYUnicycive Therapeutics9119.71 million78.78 millionNot OptionableBCAB, UNCY, CNTX, and QNCX HeadlinesRecent News About These CompaniesSilverarc Capital Management LLC Has $1.98 Million Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)April 24, 2025 | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Now Covered by Analysts at GuggenheimApril 23, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Purchased by Vivo Capital LLCApril 23, 2025 | marketbeat.comGuggenheim Initiates Coverage of Unicycive Therapeutics (UNCY) with Buy RecommendationApril 22, 2025 | msn.comUnicycive Therapeutics (NASDAQ:UNCY) Earns Buy Rating from Analysts at GuggenheimApril 22, 2025 | americanbankingnews.comUnicycive Therapeutics initiated with a Buy at GuggenheimApril 22, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Unicycive Therapeutics (NASDAQ:UNCY)April 13, 2025 | marketbeat.comUnicycive presents new patient-level data from Phase 2 study of OLCApril 12, 2025 | markets.businessinsider.comResearch Analysts Offer Predictions for UNCY FY2025 EarningsApril 6, 2025 | marketbeat.comHC Wainwright Analysts Reduce Earnings Estimates for UNCYApril 6, 2025 | marketbeat.comBrookline Capital Management Estimates UNCY Q1 EarningsApril 5, 2025 | marketbeat.comUnicycive Therapeutics price target raised to $7.50 from $4 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comNoble Financial Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)April 2, 2025 | markets.businessinsider.comHC Wainwright Increases Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $7.50April 2, 2025 | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPSApril 1, 2025 | marketbeat.comUnicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comUnicycive Therapeutics reports FY24 EPS (56c), consensus (51c)April 1, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.comUnicycive to present patient reported outcomes data from UNI-OLC-201 studyMarch 13, 2025 | markets.businessinsider.comUnicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of HyperphosphatemiaMarch 13, 2025 | globenewswire.comUnicycive Therapeutics’ OLC shows synergy with tenapanor in published studyFebruary 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCAB, UNCY, CNTX, and QNCX Company DescriptionsBioAtla NASDAQ:BCAB$0.44 +0.00 (+0.98%) Closing price 04:00 PM EasternExtended Trading$0.42 -0.02 (-5.15%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Context Therapeutics NASDAQ:CNTX$0.94 +0.00 (+0.01%) Closing price 04:00 PM EasternExtended Trading$1.00 +0.05 (+5.84%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Quince Therapeutics NASDAQ:QNCX$1.13 -0.10 (-7.89%) Closing price 03:59 PM EasternExtended Trading$1.14 +0.01 (+1.06%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Unicycive Therapeutics NASDAQ:UNCY$0.65 +0.01 (+1.34%) Closing price 04:00 PM EasternExtended Trading$0.64 -0.01 (-2.10%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
